Monte Rosa prices $100M public offering of common stock and pre-funded warrants

Monte Rosa Therapeutics, Inc.

Priced 10.6M shares at $4.70/share and pre-funded warrants for 10.6M shares at $4.6999/warrant; gross proceeds $100M.
Net proceeds ~$96.7M; expected close May 20, 2024; led by Dimension and a life-sciences institutional investor.
Funds to advance MRT-6160, MRT-8102 clinical programs and QuEEN platform; cash runway into H1 2027.
Underwriters: TD Cowen and Wedbush PacGrow.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Monte Rosa Therapeutics, Inc. entered into Underwriting Agreement with TD Securities (USA) LLC, as representative of the several underwriters valued at approximately $96.7 million (effective 2024-05-15).

Action: entry
Agreement: underwriting
Counterparty: TD Securities (USA) LLC, as representative of the several underwriters
Value: approximately $96.7 million
Effective: 2024-05-15

Exact text from the filing

On May 15, 2024, Monte Rosa Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, as representative of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), related to an underwritten public offering

View on SEC.gov

294 material agreements filed in the last 30 days. Browse all material agreements →

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-140533

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.